Evolus attracts buy rating from Needham at $18 price target

Jun. 23, 2022 11:10 AM ETEvolus, Inc. (EOLS)By: Shweta Agarwal, SA News Editor4 Comments
  • Evolus (NASDAQ:EOLSshares are up 5.3% in early trading on Wednesday after Needham started off coverage on this medical aesthetic company with a Buy Rating.
  • Analyst Serge Belanger has set a price target of $18 on Evolus, citing it as a "aesthetics emerging star." That implies a potential upside of 56% on stock's last close.
  • Wall Street analysts, on an average, give a Strong Buy rating with a average price target of $16.14 while Seeking Alpha Quant rating is at Hold. Take a quick look through Quant's factor grades on Evolus:
  • Earlier: Evolus stock rises as Q1 revenue soars 177% Y/Y

Recommended For You

Comments (4)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.